The research question
Which treatment attributes matter most, and what trade-offs are patients willing to consider?
Proposed design
Qualitative interviews to define relevant attributes, followed by a scoped preference survey if needed. Formal choice experiments require a separate statistical design.
Illustrative design: one interview or survey per participant; setup and recruitment are scoped separately.
Data to collect
- Attribute priorities
- Dosing and administration preferences
- Perceived benefits and concerns
- Access and cost considerations
Planned outputs
- Prioritized treatment attributes
- Language for a future preference instrument
- Exploratory preference segments
What we confirm with you
We agree the population, sample size, country, collection tools, analysis plan and budget. Collection starts after the required consent, ethics or other permissions and a signed scope are in place.
- Avoid suggesting treatment changes
- Validate attribute wording with participants
- Use specialist design for regulatory or quantitative benefit-risk claims
Clinical records, laboratory results, photographs and device integrations are included only when access, collection quality and permitted use have been verified. Self-reported findings are identified as such.
Research context
These published sources explain the research need or method. They are not RIDLY customers, endorsements or purchase commitments.
- FDA draft ICH E22 patient preference guidance
The February 2026 draft addresses patient preference study design. It is a research signal, not final implementation guidance.
- FDA patient-focused research methods
FDA describes methods for collecting patient and caregiver experience for medical product development.
Related dataset profiles
For an existing-data inquiry, start with a coverage review.